Long‐term oncological and continence outcomes after laparoscopic radical prostatectomy: a single‐centre experience
Jonas Busch(Charité - Universitätsmedizin Berlin), Ahmed Magheli(Johns Hopkins University), Carsten Stephan(Charité - Universitätsmedizin Berlin), Barbara Erber(Charité - Universitätsmedizin Berlin), Stefan Hinz(Charité - Universitätsmedizin Berlin), Anja Herold(Charité - Universitätsmedizin Berlin), Michael Lein(Charité - Universitätsmedizin Berlin), Kurt Miller(Charité - Universitätsmedizin Berlin), Steffen Weikert(St. Hedwig-Krankenhaus), Carsten Kempkensteffen(Charité - Universitätsmedizin Berlin)
Cited by 37
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
|Clinical Chemistry|2008|1.1k
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k